Lead Pharma has developed a distinct, proprietary platform to identify and develop innovative small molecule drugs. It has unparalleled expertise in the discovery and optimization of novel chemotypes. This capability comes from close collaboration of researchers in Lead Pharma's X-ray crystallography, computational, protein, and medicinal chemistry groups.


The company's chemistry experts are complemented by groups with expertise in cell biology and various -omics technologies. They are exploring and characterizing protein-based pathways. The platform includes capabilities to isolate, purify and manufacture target proteins and to develop biochemical, cellular and functional reporter assays as well as biomarkers. The company has acquired state-of-the-art research laboratories and equipment from the former MSD-Organon organization in Oss, the Netherlands.


Lead Pharma currently has a team of 28 FTEs, 14 of which hold a PhD in Chemistry or Biology. Many employees have long-term experience working in large pharmaceutical and/or biotech companies, including Organon, Schering-Plough, Merck, Janssen Pharmaceutica, Crucell, BioMérieux, Unilever and Numico.